知镜 Cognispect · 医学文献与研究工作台

Timing and prognosis of brain metastasis development in breast cancer by subtype.

Rashid NS, Lamba N, Ricca I, Johnson M, Catalano PJ, Tanguturi SK, Rahman R, Haas-Kogan DA, Wen PY, Sammons SL, Lin NU, Aizer AA.
JNCI cancer spectrum · 2026-09-01 · PMID 42776601

文献摘要

Limited data on the timing of brain metastases development and subsequent prognosis by breast cancer subtype exist. We retrospectively evaluated a cohort of 671 patients diagnosed with brain metastases secondary to breast cancer. Patients were categorized by subtype: human epidermal growth factor receptor 2-positive (HER2+), hormone receptor-positive/HER2-negative (HR+/HER2-), and triple negative (TN). We found significant heterogeneity in the timing of brain metastases development and subsequent prognosis by subtype. Patients with HR+/HER2- disease developed brain metastases later in the disease course compared to patients with HER2+ and TN disease. Median overall survival (OS) following the diagnosis of brain metastases was shortest in patients with TN disease; however, among all subtypes, OS decreased with an increasing number of systemic therapies received before the diagnosis of brain metastases. Altogether, these findings may inform differential timing of brain-directed screening imaging in patients with breast cancer.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。